Drug Sensitivity in Acute Myeloid Leukaemia Patients
Author Information
Author(s): J.-P. Marie, R. Zittoun, D. Thevenin
Primary Institution: Laboratoire de cinetique et de culture cellulaire, Service d'Hematologie de l'H6tel-Dieu, Paris
Hypothesis
The study investigates whether the drug sensitivity of clonogenic leukaemic cells changes in patients with acute myeloid leukaemia during treatment and relapse.
Conclusion
The study found that drug sensitivity in leukaemic cells does not significantly change after treatment, suggesting that treatment failures may be due to factors other than the selection of resistant cell clones.
Supporting Evidence
- The sensitivity of leukaemic cells remained stable for daunorubicin and showed little variation for ara-C after treatment.
- Induction treatment failures could be related to factors other than the selection of a resistant CFU-L subclone.
- Patients who achieved complete remission had different drug sensitivities at relapse compared to diagnosis.
Takeaway
The study looked at how well leukaemia cells respond to drugs in patients. It found that even after treatment, the cells didn't become more resistant, which means other reasons might cause treatment to fail.
Methodology
The study used in vitro assays to test the drug sensitivity of clonogenic leukaemic cells from bone marrow samples of patients before and after treatment.
Potential Biases
Potential bias due to the limited number of patients and the specific treatment protocols followed.
Limitations
The small sample size and the short interval between in vitro studies may not adequately capture the development of drug resistance.
Participant Demographics
Patients were adults with a mean age of 55 years, including various subtypes of acute myeloid leukaemia.
Statistical Information
P-Value
p=0.006
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website